ArticlePloS one2017
Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2022Pooled it
- Trial
- Nature Medicine Commission on dialysis policy in low- and middle-income countries.Nature medicine · 2026Article
- Cardiovascular Mortality and Its Risk Factors in Patients on Twice-Weekly Maintenance Hemodialysis: An 18-Month Retrospective Cohort Study from a Tertiary Center in Indonesia.International journal of nephrology and renovascular disease · 2026Article
- A cost- effectiveness and resource requirement comparison to optimize renal dialysis policies in Brunei Darussalam.Communications medicine · 2025Article
- Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.Nature reviews. Nephrology · 2025Review
- Setting priorities for healthcare interventions in Indonesia: a comprehensive conceptual framework.International journal for equity in health · 2025Review
- International Home Dialysis Consortium: Declaration Advocating for the Promotion of Home Dialysis Globally.Kidney international reports · 2025Article
- The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions.Kidney research and clinical practice · 2025Article
- One-year Survival of End-Stage Kidney Disease Patients Undergoing Hemodialysis in Indonesia.International journal of nephrology and renovascular disease · 2025Article
- Cost-Utility Analyses of Hemodialysis, Peritoneal Dialysis, and Kidney Transplantation in Patients with End-Stage Kidney Disease: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2025Review
- The direct cost of chronic kidney disease (CKD) reported in Asian countries; a systematic literature review.Cost effectiveness and resource allocation : C/E · 2024Article
- Rapid cost-effectiveness analysis: hemodialysis versus peritoneal dialysis for patients with acute kidney injury in Rwanda.Cost effectiveness and resource allocation : C/E · 2024Article
- Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?BMC nephrology · 2024Article
- Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings.Drugs in context · 2024Article
- Overview of global healthcare policies for patients with chronic kidney disease: an integrative literature review.Einstein (Sao Paulo, Brazil) · 2024Review
- Economic evaluation of dialysis and comprehensive conservative care for chronic kidney disease using the ICECAP-O and EQ-5D-5L; a comparison of evaluation instruments.Cost effectiveness and resource allocation : C/E · 2023Article
- Psychometric properties of kidney disease quality of life-36 (KDQOL-36) in dialysis patients in Indonesia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model.BMC research notes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD) in Indonesia.
methodsA Markov model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Three policy options were compared, i.e., the PD-first policy, HD-first policy, and supportive care.
resultsThe PD-first policy for ESRD patients resulted in 5.93 life years, equal to the HD-first policy, with a slightly higher QALY gained (4.40 vs 4.34). The total lifetime cost for a patient under the PD-first policy is around 700 million IDR, which is lower than the cost under the HD-first policy, i.e. 735 million IDR per patient. Compared to supportive care, the incremental cost-effectiveness ratio of the PD-first policy is 193 million IDR per QALY, while the HD-first policy resulted in 207 million IDR per QALY. Budget impact analysis indicated that the required budget for the PD-first policy is 43 trillion IDR for 53% coverage and 75 trillion IDR for 100% coverage in five years, which is less than the HD-first policy, i.e. 88 trillion IDR and 166 trillion IDR.
conclusionsThe PD-first policy was found to be more cost-effective compared to the HD-first policy. Budget impact analysis provided evidence on the enormous financial burden for the country if the current practice, where HD dominates PD, continues for the next five years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.